Cancer can affect people of all ages, and approximately one in three people are estimated to be diagnosed with cancer during their lifetime. Extensive research is being undertaken by many different institutions to explore potential new therapeutics, and biomaterials technology is now being developed to target, treat and prevent cancer. This unique book discusses the role and potential of biomaterials in treating this prevalent disease.
The first part of the book discusses the fundamentals of biomaterials for cancer therapeutics. Chapters in part two discuss synthetic vaccines, proteins and polymers for cancer therapeutics. Part three focusses on theranosis and drug delivery systems, whilst the final set of chapters look at biomaterial therapies and cancer cell interaction.
This extensive book provides a complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancer. Biomaterials for cancer therapeutics is an essential text for academics, scientists and researchers within the biomedical industry, and will also be of interest to clinicians with a research interest in cancer therapies and biomaterials.
A complete overview of the latest research into the potential of biomaterials for the diagnosis, therapy and prevention of cancerDiscusses the fundamentals of biomaterials for cancer therapeuticsDiscusses synthetic vaccines, proteins and polymers for cancer therapeutics

Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy, 3rd Edition, includes clinical trial results of more than 250 state-of-the-art targeted therapy and immunotherapy agents, providing a practical, intuitive, colorful overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Drs. Daniel D. Karp, Gerald S. Falchook, and JoAnn D. Lim, helps you navigate through the newest research reports and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of investigational targeted agents and combinations of agents. This handbook presents information distilled by dozens of translational research clinicians and other healthcare experts with hundreds of years of cumulative experience in the revolutionary area of genomically based precision oncology. Covers cancer targets-phase 1, 2, and 3 trials and preliminary results, as well as approved therapies. Includes sections on Molecular Targets and Pathways, and Targeted and Immunotherapy Agents. Contains a section on Carcinogenesis from the Perspective of Targeted Therapy and Immunotherapy, with essential content on biology, immunology, and immunotherapy. Organizes information by tumor type, pathway, and drug name, so you can approach clinical challenges from any direction. Highlights FDA approvals throughout. Pocket-sized and color coded to help you find information quickly and easily. Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech.

Cancer will remain a global major health problem unless new diagnostic, prognostic, and management approaches are discovered to address both loss of life and quality of life. Here we summarize the general physiology, pathology, heterogeneity, and evolution of cancer, current status, limitations and challenges associated with prevention, incidence, treatment, survival, and mortality, as well as future directions with regards to solid tumors. Perspectives are provided on how to improve pre-clinical understandings, outcomes, and patient care. Further, this comprehensive, timely overview of the literature has educational value as part of an academic course, seminar, or as a supplementary text. Features : This book summarizes the current status, successes, difficulties, advancements, limitations, and challenges in medical interventions that impact patients' quality of life. Includes concise descriptions of all relevant cell and molecular biology concepts including evolutionary paradigms, hallmarks of cancer, and heterogeneity to help understand the pathophysiology of cancer, cancer-associated disease conditions, and effective cancer therapy. Contains an array of colorful figures and schematics summarizing complex informative pathological, physiological, and biochemical concepts. Covers a multitude of sub-topics pertaining to cancer biology including diagnosis; chemotherapy, radiotherapy and targeted therapy; metastasis; disseminated and circulating tumor cells, and cancer stem cells; drug resistance and cellular reprogramming; complex epigenetics; tumor-derived exosomes; oncogenic viruses; metabolic syndrome and cancer metabolism; convoluted neovascularization; efficient biomarkers; immunotherapy; role of nutraceuticals and natural products. Provides perspectives on how to improve pre-clinical understandings, and outcomes, linking toxicological, and pharmacological aspects in patient care. This timely, relevant comprehensive assortment of scientific literature has educational value to a wider audience including as part of an academic course, seminar, or as a supplementary text.

Gives a convenient summary of trials in Gynecologic Oncology Supplies an invaluable revision primer for those undertaking certification Provides a uniquely up-to-date resource

Spreading to every corner of the Earth, the COVID-19 virus has had an unparalleled impact on all aspects of our lives. This book explores in detail how the COVID-19 pandemic has affected clinical practice, education, and research in medical physics, and how colleagues on the frontline dealt with this unpredictable and unprecedented pandemic. It tackles key questions such as: How did medical physicists first respond to the situation? What innovative strategies were taken and how effective were they? How are medical physicists preparing for the future? There will be a focus on the different experiences of regional medical physicists and the responses and outlooks in clinical practice, education, and research in the affected continents, Asia-Pacific, the Middle East, Europe, Africa and North and Latin America. With over 91 contributors from 39 countries, this unique resource contains key perspectives from teams from each territory to ensure a global range of accounts. The collective opinion and wisdom from the major medical physics journal editors-in-chief are also explored, alongside how the pandemic has affected the quantity and quality of publications. Voices of early-career researchers and students of medical physics will be included, with narratives of their experiences coping with life during the pandemic. Lastly, communicating leadership in times of adversity is highlighted. This book will be a historic account of the impact of the COVID-19 virus on the field of medical physics. It will be an ideal reference for medical physicists, medical physics trainees and students, hospital administrators, regulators, and healthcare professionals allied with medical physics. Key features: The first book to cover the impact of COVID-19 on the field of medical physics Edited by two experts in the field, with chapter contributions from subject area specialists around the world Broad, global coverage, ranging from the impact on teaching, research, and publishing, with unique perspectives from journal editors and students and trainees

The first comprehensive and most recent overview of the topic, this ready reference and handbook reviews current knowledge of TAAs, their subclasses, and pinpoints their application areas in medicine. In addition, it emphasizes target identification procedures, the need for an accurate and thorough analysis of the function of TAAs, and the validation of those in clinical settings. The whole is rounded off with an overview of currently approved therapeutic antibodies.
The result is a must-have for biologists and oncologists in science, clinics and industry.

Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

Outlining the unique psychosocial and development issues faced by young adults affected by cancer, this text draws on qualitative data from two pilot studies conducted in the United States to illustrate how the needs of this often-overlooked population can be effectively met via group therapy in clinical settings. Drawing on 25 years of experience as a licensed clinical social worker supporting pediatric and young adult cancer patients and their families, Kurker focuses on the role of the clinician in structuring support group sessions. Chapters draw on patient perspectives to demonstrate effective application of interventions to help adolescents work through trauma associated with a diagnosis of cancer, treatment, recovery and the impacts on their development. Outcomes from these studies also include strategies for selecting support group participants, structuring group activities and securing funding. Effective Group Therapies for Young Adults Affected by Cancer will be a valuable text for oncology social workers and clinicians involved in adolescent support services. In addition, researchers and postgraduate students with an interest in the fields of social work, psychology and adolescent development will find the book of interest.

A comprehensive, down-to-earth guide for anyone diagnosed with breast cancer. Being diagnosed with breast cancer can be scary and confusing. There are medical terms to learn, options to consider, and important decisions to make, all while trying to carry on with work, family, and life. The Breast Cancer Book can't reverse a diagnosis or make breast cancer disappear, but every page can inform and empower you or your loved ones, no matter where you are in the breast cancer experience. Written by three trusted experts-an oncologist, a breast surgeon, and a two-time breast cancer survivor-this multidisciplinary book walks you through everything you need to know about breast cancer so that you can make the best decisions about diagnosis, treatment, and follow-up care. In plain, easy-to-understand language that illuminates all the facets of this disease, the authors draw on their professional experience and the most current scientific knowledge to * describe the risk factors for breast cancer; * explain the various tests used to detect cancer; * clarify the full range of treatment options, from surgery, chemotherapy, and radiation to newer combination therapies; * provide insight from experts in genetics, radiation oncology, and breast reconstruction; * present inspirational true stories of breast cancer survivors; and * simplify complex concepts with detailed graphics, tables, illustrations, and photographs. A crash course on breast cancer that will help get you or anyone you love through the physical and emotional challenges of the disease, The Breast Cancer Book will also help readers communicate with their cancer team. Packed with information, this compassionate guide is the most up-to-date book available.

This comprehensive and useful handbook represents a definitive up-to-date compendium of key in vitro bioassay methods that are employed to quantify and validate the anticancer activity of a drug candidate before it makes its way in to animal or clinical trials. In Vitro Bioassay Techniques for Anticancer Drug Discovery and Development covers the screening and evaluation of potential drug candidates in a wide category of anticancer assays demonstrating the specific ways in which various pharmaceutical bioassays interpret the activity of drug molecules. The major emphasis of the book is to present those bioassays which can be readily set up and practiced in any laboratory with limited funds, facilities or technical know-how.

Differential gene regulation and targeted therapy are the critical aspects of several cancers. This book covers specific gene regulation and targeted therapies in different malignancies. It offers a comprehensive assessment of the transcriptional dysregulation in cancer, and considers some examples of transcriptional regulators as definitive oncogenic drivers in solid tumors, followed by a brief discussion of transcriptional effectors of the programs they drive, and discusses its specific targets. Most targeted therapeutics developed to date have been directed against a limited set of oncogenic drivers, exemplified by those encoding cell surface or cytoplasmic kinases that function in intracellular signaling cascades.

Statistical Approaches in Oncology Clinical Development : Current Paradigm and Methodological Advancement presents an overview of statistical considerations in oncology clinical trials, both early and late phase of development. It illustrates how novel statistical methods can enrich the design and analysis of modern oncology trials. The authors include many relevant real life examples from the pharmaceutical industry and academia based on their first-hand experience. Along with relevant references, the book highlights current regulatory views. The book covers all aspects of cancer clinical trial starting from early phase development. The early part of the book covers novel phase I dose escalation design, exposure response analysis, and innovative phase II design. This includes early development strategy for cancer immunotherapy trials. The contributors also emphasized the role of biomarker and modern era of precision medicine. The second part focuses on the late stage development. This includes the application of adaptive design, safety analysis, and quality of life (QoL) data analysis. The final part discusses current regulatory perspective and challenges. Features: Covers a wide spectrum of topics related to real-life statistical challenges in oncology clinical trials. Provides a comprehensive overview of novel statistical methods to improve trial design and statistical analysis. Detailed case studies illustrate the real life applications. Satrajit Roychoudhury is a Senior Director and a member of the Statistical Research and Innovation group in Pfizer Inc. Prior to joining; he was a member of Statistical Methodology and consulting group in Novartis. He has 11 years of extensive experience in working with different phases of clinical trial. His area of research includes early phase oncology trials, survival analysis, model informed drug development, and use of Bayesian methods in clinical trials. He is industry co-chair for the ASA Biopharmaceutical Section Regulatory-Industry Workshop and has provided statistical training in major conferences including the Joint Statistical Meetings, ASA Biopharmaceutical Section Regulatory-Industry Workshop, and ICSA Applied Statistics Symposium. Soumi Lahiri has 12 years of extensive experience in working different therapeutic areas. She is the former Director of Biostatistics in Clinical Oncology, GlaxoSmithKline. She has also worked in the oncology division of Novartis Pharmaceutical Company for two years. She is an active member of the ASA Biopharmaceutical section and former chair of the membership committee.

The biological function of clusterin (CLU, also known as ApoJ, SGP2, TRPM2, CLI) has been puzzling researchers since its discovery and characterization in the early 1980s. Approaches such as cloning, expression and functional characterization of the different protein products generated by the CLU gene have now produced a critical mass of information of tremendous biological importance that are teaching us an important lesson in molecular biology of gene expression regulation. This volume brings together the contributions of top researchers in the field, providing an overview and synthesis of the latest thought and findings relating to CLU.

Cancer is a dreaded disease. One in two people will be diagnosed with cancer within their lifetime. Medical Statistics for Cancer Studies shows how cancer data can be analysed in a variety of ways, covering cancer clinical trial data, epidemiological data, biological data, and genetic data. It gives some background in cancer biology and genetics, followed by detailed overviews of survival analysis, clinical trials, regression analysis, epidemiology, meta-analysis, biomarkers, and cancer informatics. It includes lots of examples using real data from the author's many years of experience working in a cancer clinical trials unit. Features: A broad and accessible overview of statistical methods in cancer research Necessary background in cancer biology and genetics Details of statistical methodology with minimal algebra Many examples using real data from cancer clinical trials Appendix giving statistics revision.

Key features include: Details the role of plants for the treatment and management of cancer and diabetes Discusses the role of phytocompounds as ligands for cancer and diabetic targets Reviews plants and the potential of phytochemicals as antidiabetic and anticancer drugs Explores the green biosynthesis of nanoparticles and their treatment efficiency

A much-needed overview of the available information now accumulating to indicate that assisted reproductive technologies are generally safe for both babies and mothers. However, the literature abounds with reports of a higher risk of obstetric and perinatal complications; regarding the long term outcomes for both women and children, the data are still scarce. The chapters summarized in this book review the current knowledge on long term safety of assisted reproduction and indicate the need for continued research to cover the lack of data in some specific patient groups and for recently developed treatments that only have a short period of follow-up.

the generative and resistant value of human vulnerability the importance of vulnerability in motivating engagement with social networks and material ecologies for productive thinking, communication, and community how relational ethics emerge as important for social and communicative life

Tumors/cancers are characterized by uncontrolled growths of abnormal cells that extend beyond their usual boundaries and disrupt the normal functions of affected organs and systems. While about 75%-80% of tumors/cancers arise sporadically without a family connection, 20%-25% appear to be familial (including 10%-15% nonhereditary familial tumors [or familial tumors] and 5%-10% hereditary familial tumors [or hereditary tumors]). As nonhereditary and hereditary familial tumors often show both tumor-related and non-tumor-related (or syndromic) symptoms, they are referred to as tumor syndromes (or cancer susceptibility syndromes). In comparison with sporadic tumors/cancers, tumor syndromes (>300 described so far) tend to occur at a younger age, involve multiple organs and systems, produce multiple (often in a distinct spectrum) and bilateral lesions, form multiple hamartomatous, benign, or precursor lesions; locate in specific site(s), display unique syndromic features, and affect multiple members/generations of a family. This book provides state-of-art and authoritative coverage of nearly 100 tumor syndromes, with chapters presenting overviews of individual tumor syndromes in relation to their biology, epidemiology, pathogenesis, clinical features, diagnosis, treatment, and prognosis. Featuring contributions from oncologists, clinicians, and specialists, the book offers a reliable, comprehensive reference on tumor syndromes for scholars and students of medicine, dentistry, pharmacology, nursing, public health, and other biomedical disciplines. Key Features Reviews the biology, epidemiology, pathogenesis, and clinical features of tumor syndromes Contains up-to-date information on the diagnosis and treatment of tumor syndromes Includes expert coverage from leading oncologists and clinicians Related Titles J. R. McIntosh, Understanding Cancer: An Introduction to the Biology, Medicine, and Societal Implications of This Disease (ISBN 978-0-8153-4535-0) P. S. T. Shanmugam, Understanding Cancer Therapies (ISBN 978-1-1381-9815-9) J. M. Baehring and J. M. Piepmeier, eds., Brain Tumors: Practical Guide to Diagnosis and Treatment (ISBN 978-0-3673-9022-8) D. Liu, Tumors and Cancers: Endocrine Glands - Blood - Marrow - Lymph (ISBN 978-1-4987-2975-8) Dongyou Liu, PhD, has worked at several research and clinical laboratories in Australia and the United States for the past three decades, with a focus on molecular characterization of microbial pathogens and detection of human genetic disorders and tumors/cancers. He is the primary author of more than 50 original research and review articles in various peer-reviewed international journals, the contributor of 197 book chapters, and the editor of more than 10 books.

Dopamine is a small molecule traditionally regarded as a brain-derived neuronal modulator implicated in many neurological and psychiatric disorders. Outside the brain, dopamine fulfills all the criteria of a circulating hormone which affects normal and abnormal functions of multiple organs and regulatory systems and is also involved in many aspects of cancer formation and progression. This book provides a much needed systematic account of dopamine as an endocrine and autocrine/paracrine hormone and fills a major gap in the overall understanding of the production, distribution and actions of this very important molecule. Key Features: Explores the many different faces of dopamine as autocrine, paracrine and endocrine molecule Documents the adverse effects of antipsychotics on dopamine functions Reviews the many ways dopamine affects the cardiovascular, renal and reproductive systems Provides updates on receptor oligomerization and signaling Examines the role of dopamine in tumorigenesis Related Titles Jones, S. ed. Dopamine - Glutamate Interactions in the Basal Ganglia (ISBN 978-0-3673-8197-4) Luo, L. Principles of Neurobiology (ISBN 978-0-8153-4494-0) Sidhu, A. et al., eds. Dopamine Receptors and Transporters (ISBN 978-0-8247-0854-2)

1) Discusses technical details of the Machine Learning tools and techniques in the different types of cancers 2) Machine learning and data mining in healthcare is a very important topic and hence there would be a demand for such a book 3) As compared to other titles, the proposed book focuses on different types of cancer disease and their prediction strategy using machine leaning and data mining.

Covers research on lipid nanosystems for use in cancer therapy and diagnostics, including aspects from physiological barriers in cancer, strategies to overcome these barriers, classical therapeutic strategies, new therapeutic options, and hyphenated approaches for synergic treatments Includes contributions from experts in different topics such as cancer pathology and treatments, triggering strategies, targeting ligands, gene therapy Contains excellent figures illustrating research highlights taken from the latest and most interesting developments in the field of functional lipid nanosystems for cancer therapy

This insightful volume opens new horizons for exploring modern therapeutic entities and emerging targets for combating the deadly disease of cancer. The authors provide a review of cancer along with descriptions of its molecular level mechanisms and emphasize the role of promising new therapies, including herbal therapies, that can be utilized for the treatment of metastatic diseases. The chapters look at specific approaches that have been researched and developed and that have almost reached the standardization stage, such as intracellular mechanisms, particularly phosphoprotein-enriched astrocytes and transthyretin proteins; CXCR4; autophagy-inhibiting drugs; spatiotemporal genetic analysis; tyrosine kinase inhibitors; and more. Also considered are advances in diagnostic systems like intra vital microscopy and molecular imaging.